BUD14 Antibody

What is BUD14 and why are antibodies against it important for yeast cell biology research?

BUD14 is a multifunctional protein in Saccharomyces cerevisiae that serves several critical roles in cell division and cytoskeletal organization. It functions as a regulatory subunit of Protein Phosphatase 1 (Glc7) and plays an essential role in mitotic exit inhibition through the Spindle Position Checkpoint (SPOC). Additionally, BUD14 acts as a high-affinity inhibitor of the yeast formin Bnr1, displacing the Bnr1 FH2 domain from growing barbed ends of actin filaments, thereby regulating actin cable formation and maintenance . More recently, BUD14 has been identified as crucial for spindle pole body (SPB) size maintenance .

Antibodies against BUD14 are valuable tools for investigating these diverse cellular functions, allowing researchers to track BUD14 localization, evaluate protein-protein interactions, assess phosphorylation states, and quantify expression levels throughout the cell cycle. These antibodies enable the visualization and characterization of BUD14's roles in spindle positioning, mitotic checkpoint regulation, and cytoskeletal dynamics in both normal and perturbed cellular states.

What detection methods are most effective when using BUD14 antibodies?

Several detection methods have proven effective for BUD14 antibody applications, each with specific advantages depending on the research question:

• Immunoblotting/Western Blotting: Effective for quantifying total BUD14 protein levels and detecting post-translational modifications. The protocol typically involves TCA precipitation of proteins from log-phase cells grown in YPAD medium . Primary antibodies against epitope-tagged BUD14 (such as BUD14-6HA) can be detected using HRP-conjugated secondary antibodies with chemiluminescence imaging systems like Bio-Rad Chemidoc MP .

• Immunofluorescence Microscopy: Valuable for studying BUD14 localization relative to other cellular structures, particularly when examining its association with spindle pole bodies. Quantitative fluorescence microscopy has been instrumental in demonstrating BUD14's role in maintaining SPB size .

• Co-immunoprecipitation: Essential for studying BUD14's interactions with binding partners such as Glc7 and Bnr1. Direct binding of BUD14 to the FH2 domain of Bnr1 has been demonstrated using bead-immobilized proteins .

• Yeast Two-Hybrid Assays: Useful for identifying novel protein interactions, as demonstrated in the discovery of BUD14's interaction with Bfa1 that requires the presence of Bub2 .

When selecting a detection method, consider the cellular compartment where BUD14 functions (cytoplasmic versus SPB-associated) and whether you're investigating total protein levels or specific protein-protein interactions.

How can researchers distinguish between BUD14's different functional roles using antibodies?

Distinguishing between BUD14's multiple functional roles requires strategic experimental design combining antibody-based techniques with genetic approaches:

• Functional Domain-Specific Antibodies: Use antibodies targeting specific domains of BUD14 involved in different interactions. For example, antibodies recognizing the Glc7-binding region versus those recognizing formin-interaction domains can help differentiate between these functions.

• Mutant Forms Analysis: Compare antibody staining patterns in cells expressing wildtype BUD14 versus mutant forms, such as BUD14-F379A, which cannot interact with the formin Bnr1 . This approach can help distinguish between BUD14's role in formin regulation versus its function in mitotic exit inhibition.

• Co-localization Studies: Perform dual-labeling experiments with antibodies against BUD14 and its different interaction partners (Glc7, Bnr1, Bfa1-Bub2) across cell cycle stages to determine when and where specific interactions occur.

• Cell Cycle Synchronization: Analyze BUD14 localization and interaction patterns in synchronized cell populations at specific cell cycle phases, particularly during anaphase when its mitotic exit inhibitory function is active .

For example, research has shown that BUD14's mitotic exit inhibitory function requires its association with Glc7, but is independent of its role in formin regulation, as a BUD14 mutant unable to bind Bnr1 remains functional for mitotic exit inhibition .

What are the optimal conditions for BUD14 antibody storage and handling?

For optimal antibody performance in BUD14 research applications, the following storage and handling guidelines are recommended:

• Storage Temperature: Store BUD14 antibodies at -20°C for long-term storage or at 4°C for antibodies in frequent use (up to 1 month).

• Aliquoting: Upon receipt, divide the antibody into small working aliquots to minimize freeze-thaw cycles, which can degrade antibody quality and reduce specificity.

• Buffer Composition: Most commercial BUD14 antibodies are supplied in buffers containing phosphate-buffered saline (PBS) with preservatives like sodium azide (0.02%) and protein stabilizers (often BSA at 1-5%). Maintain these conditions when diluting working stocks.

• Working Dilutions: Optimal working dilutions vary by application:

  • Western blot: Typically 1:1000-1:5000

  • Immunofluorescence: Typically 1:100-1:500

  • Immunoprecipitation: Typically 1-5 μg antibody per 100-500 μg total protein

• Validation Controls: Always include appropriate controls in experiments, including:

  • Positive control: Wildtype yeast expressing BUD14

  • Negative control: bud14Δ yeast strains

  • Secondary antibody-only control: To assess background staining

Adherence to these guidelines will ensure consistent and reliable results when using BUD14 antibodies for research applications.

How can BUD14 antibodies be used to investigate its role in mitotic exit inhibition?

BUD14 antibodies can be strategically employed to dissect its role in mitotic exit inhibition through several sophisticated approaches:

• Phosphorylation-State Specific Antibodies: Develop or use antibodies that recognize phosphorylated versus non-phosphorylated forms of BUD14 to monitor how its phosphorylation state changes during spindle misalignment and mitotic exit. This approach can help determine whether BUD14's activity in the Spindle Position Checkpoint (SPOC) is regulated by phosphorylation.

• Sequential Chromatin Immunoprecipitation (ChIP-reChIP): Use BUD14 antibodies in conjunction with antibodies against SPOC components like Kin4, Bfa1, and Bub2 to identify multi-protein complexes that form during spindle misalignment events.

• Proximity Ligation Assays (PLA): Apply this technique to visualize and quantify in situ interactions between BUD14-Glc7 and downstream SPOC effectors like Bfa1-Bub2, which would provide spatial and temporal resolution of these interactions during mitosis.

• Live-Cell Imaging with Immunofluorescence Confirmation: Combine live imaging of fluorescently tagged BUD14 with fixed-cell immunofluorescence using BUD14 antibodies to correlate dynamic behaviors with protein modification states.

Research has demonstrated that BUD14, in association with Glc7, works parallel to the SPOC kinase Kin4 in regulating Bfa1, the most downstream effector of SPOC that inhibits mitotic exit . Furthermore, BUD14 promotes Bfa1 dephosphorylation during anaphase, as cells lacking BUD14 accumulate hyperphosphorylated Bfa1 forms . This suggests that BUD14-Glc7 counteracts the Polo kinase Cdc5's phosphorylation of Bfa1, a critical regulatory event in mitotic exit control.

What methodological approaches can resolve contradictory findings regarding BUD14 localization patterns?

Resolving contradictory findings about BUD14 localization requires sophisticated methodological approaches that can accommodate the protein's dynamic behavior across different cell cycle stages and experimental conditions:

• Super-Resolution Microscopy: Techniques such as Structured Illumination Microscopy (SIM) or Stochastic Optical Reconstruction Microscopy (STORM) using BUD14 antibodies can provide nanometer-scale resolution of BUD14 localization, distinguishing between diffuse cytoplasmic pools and concentrated foci at specific cellular structures.

• Cell Cycle-Specific Analysis: Implement precise cell cycle synchronization methods combined with time-resolved immunofluorescence to track BUD14 localization patterns across mitotic phases. This approach has revealed that while BUD14 itself is not enriched at spindle poles, its binding partner Glc7 localizes to spindle poles specifically in cells with misaligned anaphase spindles .

• Differential Detergent Extraction: Prior to antibody staining, use graduated detergent extraction protocols to distinguish between soluble and insoluble/cytoskeletal-associated BUD14 populations, which may explain apparently contradictory localization patterns.

• Epitope Masking Assessment: Perform parallel immunofluorescence experiments with antibodies targeting different regions of BUD14 to determine whether certain interaction contexts might mask epitopes and lead to false-negative localization results.

Research has shown that despite BUD14 not being enriched at spindle poles, Glc7 (its binding partner) localizes to the spindle poles in cells with misaligned anaphase spindles, indicating the proximity of Glc7 to Bfa1 during anaphase . Additionally, bud14Δ cells have increased Bfa1, Bub2, and Tem1 localized to SPBs, especially at the daughter-oriented SPB, suggesting BUD14 may function in limiting SPB-bound levels of these proteins . These findings help reconcile seemingly contradictory observations about BUD14's functional significance at SPBs despite its apparent absence from these structures.

How can researchers quantitatively assess BUD14's impact on spindle pole body protein dynamics?

Quantitative assessment of BUD14's impact on spindle pole body (SPB) protein dynamics requires precise measurement techniques and appropriate controls:

• Ratiometric Fluorescence Quantification: Use ratiometric approaches comparing fluorescence intensities of SPB proteins to an internal standard in wildtype versus bud14Δ cells. This method has revealed that cells lacking BUD14 have increased levels of inner, outer, and central plaque proteins at SPBs during anaphase .

• Fluorescence Recovery After Photobleaching (FRAP): Apply this technique to measure the turnover rates of SPB proteins in the presence and absence of BUD14, which can reveal whether BUD14 affects the dynamic exchange of components at the SPB.

• Single-Molecule Tracking: Implement single-molecule tracking of fluorescently labeled SPB proteins to determine residence times and binding/unbinding kinetics at SPBs in wildtype versus bud14Δ backgrounds.

• Cell Cycle-Specific Quantification Protocol: The following standardized protocol has proven effective:

Research has shown that during α-factor-induced G1-arrest, inner and outer plaque proteins respond differently to the absence of BUD14. While Nud1 and Spc72 levels equalize between wildtype and bud14Δ cells during this arrest, Spc110 shows a dramatic reduction in bud14Δ cells compared to wildtype cells . During nocodazole-induced M-phase arrest, bud14Δ cells consistently show elevated levels of all three SPB proteins (Nud1, Spc72, and Spc110) . These differential responses across cell cycle stages provide important insights into the temporal regulation of SPB size by BUD14.

What are the technical considerations for using BUD14 antibodies in co-immunoprecipitation studies with Glc7?

Co-immunoprecipitation (co-IP) studies investigating BUD14-Glc7 interactions present several technical challenges requiring specific optimization:

• Epitope Accessibility Concerns: The BUD14-Glc7 interaction involves a specific binding region that may be partially masked in certain contexts. When designing co-IP experiments, consider using antibodies targeting regions of BUD14 away from the Glc7-binding interface to avoid interference with the interaction. Research has shown that BUD14's association with Glc7 is critical for its mitotic exit inhibitory function .

• Salt and Detergent Optimization: BUD14-Glc7 interactions may be sensitive to extraction conditions. A gradient testing approach is recommended:

• Phosphatase Inhibitor Considerations: Since Glc7 is a phosphatase and the BUD14-Glc7 complex regulates phosphorylation states of targets like Bfa1, the choice of phosphatase inhibitors is critical. Include 1 mM sodium orthovanadate for tyrosine phosphatases and 10 mM sodium fluoride for serine/threonine phosphatases, but be aware these may affect certain aspects of Glc7 activity.

• Cross-Linking Approach: For transient or dynamic interactions, consider a mild formaldehyde cross-linking step (0.1-0.5% for 10 minutes at room temperature) prior to cell lysis to capture physiologically relevant complexes.

• Sequential Immunoprecipitation Strategy: To isolate specific BUD14-Glc7 complexes from the broader pool of Glc7 interactions (as Glc7 has many regulatory subunits), employ a sequential IP approach:
  a) First IP with BUD14 antibodies
  b) Gentle elution with peptide competition
  c) Second IP with Glc7 antibodies
  d) Analysis of resulting complexes for additional interactors

Research has demonstrated that the mitotic exit inhibitory function of BUD14 requires its association with Glc7, and disrupting this interaction (either through temperature-sensitive Glc7 mutations or BUD14 mutations that prevent Glc7 binding) causes spindle position checkpoint deficiencies . These findings highlight the importance of accurately preserving and detecting this critical interaction.

What approaches can differentiate between BUD14's roles in formin regulation versus spindle pole body maintenance?

Differentiating between BUD14's distinct cellular functions requires sophisticated experimental design combining genetic, biochemical, and microscopy approaches:

• Domain-Specific Mutant Analysis: Utilize BUD14 mutants with specific functional impairments:

  • BUD14-F379A: Cannot interact with the formin Bnr1 but retains Glc7 binding

  • BUD14 mutants defective in Glc7 binding but retaining Bnr1 interaction

  By comparing phenotypes of these mutants using BUD14 antibodies, researchers can attribute specific cellular outcomes to distinct functional domains.

• Temporal Resolution of Functions: Implement cell cycle synchronization combined with rapid protein degradation systems (such as auxin-inducible degrons) to deplete BUD14 at specific cell cycle stages, then use antibodies to assess immediate consequences on:

  • Actin cable structure (formin regulation function)

  • SPB protein composition (SPB maintenance function)

  • Mitotic checkpoint integrity (SPOC function)

• Biochemical Separation of Complexes: Fractionate cell lysates to separate cytoskeletal fractions (containing formin-related complexes) from SPB-enriched fractions, then perform immunoblotting with BUD14 antibodies to determine the relative distribution of BUD14 between these compartments under various conditions.

• Genetic Interaction Profiling: Compare genetic interaction patterns of bud14Δ with mutations affecting specifically:

  • Actin cytoskeleton (e.g., tpm1Δ, aip1Δ)

  • SPB structure (e.g., spc110 mutants)

  • Mitotic exit (e.g., lte1Δ, kin4Δ)

Research has shown that bud14Δ has opposite genetic interactions with tpm1Δ and aip1Δ, supporting the model that loss of BUD14 results in elongated and bent cables comprised of abnormally long actin filaments . Additionally, BUD14's role in SPB maintenance appears independent of its formin regulatory function, as demonstrated by its impact on SPB protein levels, particularly Spc110 . Furthermore, a BUD14 mutant that cannot bind to the formin Bnr1 remained functional for mitotic exit inhibition, indicating separation between these functions .

What controls are essential when using BUD14 antibodies in immunofluorescence experiments?

Rigorous controls are critical for generating reliable immunofluorescence data with BUD14 antibodies:

• Genetic Controls: Always include the following strains:

  • bud14Δ cells: Essential negative control to establish antibody specificity

  • GFP-tagged or epitope-tagged BUD14 strains: For antibody validation and co-localization studies

  • BUD14 domain mutants: To establish domain-specific functions (e.g., BUD14-F379A mutant that cannot bind Bnr1)

• Technical Controls:

  • Secondary antibody-only control: To assess non-specific binding

  • Peptide competition: Pre-incubate antibody with excess cognate peptide to confirm specificity

  • Cross-reactivity panel: Test antibody against related proteins, particularly those with structural similarity to BUD14

• Cell Cycle Controls: Include synchronized populations representing key cell cycle stages:

  • G1 (α-factor arrest): Important for assessing SPB protein dynamics

  • M-phase (nocodazole arrest): Critical for evaluating BUD14's role in mitotic processes

  • Anaphase cells: Essential for studying BUD14's role in spindle positioning and mitotic exit

• Quantification Standards: For fluorescence intensity measurements, implement:

  • Internal reference standards (e.g., co-staining with tubulin)

  • Calibration beads for absolute intensity standardization

  • Consistent imaging parameters across all experimental conditions

Research has demonstrated that BUD14's impact on SPB proteins varies dramatically across cell cycle stages. During α-factor-induced G1-arrest, Spc110 levels at SPBs are reduced in bud14Δ cells compared to wildtype, while during nocodazole-induced M-phase arrest, bud14Δ cells show elevated levels of Nud1, Spc72, and Spc110 . These cell cycle-dependent effects highlight the importance of proper controls when studying BUD14's functions.

How can researchers optimize antibody-based techniques for studying BUD14 in non-yeast model systems?

While BUD14 is primarily studied in Saccharomyces cerevisiae, researchers investigating homologous proteins in other systems can optimize antibody-based approaches through the following strategies:

• Epitope Conservation Analysis: Before selecting antibodies for non-yeast studies, perform sequence alignment of BUD14 homologs to identify conserved epitopes most likely to be recognized across species. Focus on functional domains with higher conservation:

  • The Glc7 (PP1) binding motif is often more conserved than species-specific regions

  • The formin-interaction domain may show conservation in organisms with similar actin regulation mechanisms

• Cross-Reactivity Testing Protocol:

• Fixation Optimization for Different Cell Types: Different cell types may require adjusted fixation protocols:

  • Mammalian cells: 4% paraformaldehyde (10 min) or methanol (-20°C, 5 min)

  • Drosophila cells: 4% formaldehyde in PBS (15 min)

  • C. elegans: Methanol/acetone (1:1) at -20°C

• Signal Amplification Strategies: For weakly conserved epitopes:

  • Tyramide signal amplification (TSA) can enhance detection sensitivity

  • Proximity ligation assay (PLA) can validate protein-protein interactions with greater sensitivity

  • Multiple antibody approach using antibodies against different regions of the putative homolog

• Validation with RNAi/CRISPR: Confirm antibody specificity in non-yeast systems by demonstrating reduced signal following knockdown or knockout of the putative homolog.

While BUD14 is specific to fungi, its interaction with Protein Phosphatase 1 (Glc7 in yeast, PP1 in mammals) represents a conserved regulatory mechanism. The methodological approaches described here can be particularly valuable for investigating proteins that regulate PP1 activity in higher eukaryotes, which may perform functions analogous to BUD14 in spindle positioning and cell division.

What are the most effective strategies for troubleshooting inconsistent BUD14 antibody staining patterns?

Inconsistent staining patterns with BUD14 antibodies can stem from multiple sources requiring systematic troubleshooting:

• Epitope Masking Analysis: BUD14's interactions with binding partners may mask antibody epitopes in specific cellular contexts:

  • Test multiple antibodies targeting different regions of BUD14

  • Employ epitope retrieval techniques, such as heating samples to 80°C in citrate buffer (pH 6.0)

  • Try partial protein denaturation with 0.5% SDS treatment before antibody application

• Cell Cycle-Dependent Variations: BUD14 localization and modification states change throughout the cell cycle:

  • Implement precise cell cycle synchronization

  • Co-stain with cell cycle markers (e.g., spindle length for mitotic stage identification)

  • Quantify staining patterns separately for each defined cell cycle stage

• Fixation Method Comparison:

• Background Reduction Strategies:

  • Implement longer blocking steps (2-3 hours) with 5% BSA or 5% normal serum

  • Add 0.1% Triton X-100 to antibody dilution buffer to reduce non-specific binding

  • Prepare affinity-purified antibodies using recombinant BUD14 protein columns

• Sample-Specific Optimization: Different experimental conditions may require specific adjustments:

  • For temperature-sensitive mutants: Fix cells rapidly after temperature shift

  • For synchronization experiments: Optimize fixation timing to capture transient states

  • For co-localization studies: Ensure compatible fixation for all target proteins

Research has shown that BUD14's association with different complexes changes throughout the cell cycle. For example, BUD14 promotes Bfa1 dephosphorylation specifically during anaphase , and its impact on SPB protein levels varies dramatically between G1 arrest and M-phase arrest conditions . These temporal dynamics must be considered when troubleshooting staining inconsistencies.

How can BUD14 antibodies be used to investigate the relationship between actin dynamics and mitotic checkpoint regulation?

BUD14's dual roles in actin organization (via formin inhibition) and mitotic exit regulation present a unique opportunity to investigate potential crosstalk between these processes:

• Cytoskeletal and Checkpoint Co-Visualization: Implement triple-labeling experiments using:

  • BUD14 antibodies

  • Actin filament markers (fluorescent phalloidin)

  • Mitotic checkpoint components (antibodies against Bfa1, Bub2, or Tem1)

  This approach can reveal spatial relationships between cytoskeletal structures and checkpoint signaling components.

• Conditional Mutation Analysis with Antibody Readouts: Combine temperature-sensitive mutations or rapid protein degradation systems targeting either:

  • Actin regulatory components (e.g., formin temperature-sensitive mutants)

  • Mitotic checkpoint components (e.g., Kin4 or Bfa1)

  Then use BUD14 antibodies to monitor changes in BUD14 localization, modification state, or interaction partners under these perturbations.

• Actin-Disrupting Drug Time-Course: Treat cells with latrunculin A (LatA) to disrupt actin filaments, then use antibodies to assess:

  • Changes in BUD14 localization

  • Alterations in BUD14's association with Glc7 versus formins

  • Effects on mitotic checkpoint component phosphorylation states

Research has shown that bud14Δ cells display fewer actin cables, which are aberrantly long, bent, and latrunculin A-resistant . Additionally, these cells exhibit multinucleated phenotypes when spindle positioning is impaired . The latrunculin A resistance assay revealed that while wild-type cells had a T₁/₂ = 27 seconds for visible cable loss, bud14Δ cells showed T₁/₂ = 53 seconds, indicating substantially more stable actin structures . These phenotypes suggest potential links between BUD14's role in actin regulation and spindle positioning that could be further explored using antibody-based approaches.

What protocols are recommended for detecting post-translational modifications of BUD14 using antibodies?

Detecting post-translational modifications (PTMs) of BUD14 requires specialized antibody-based protocols:

• Phosphorylation-Specific Detection:

  • Phospho-specific antibodies: If available, use antibodies specifically raised against phosphorylated BUD14 peptides

  • Phospho-enrichment prior to detection: Implement titanium dioxide (TiO₂) or immobilized metal affinity chromatography (IMAC) to enrich phosphorylated BUD14 before antibody detection

  • Phosphatase treatment controls: Compare antibody reactivity in samples with and without lambda phosphatase treatment

• Modified Immunoprecipitation Protocol for PTM Detection:

• 2D Gel Electrophoresis with BUD14 Antibodies: Separate BUD14 based on charge (influenced by phosphorylation) in the first dimension and molecular weight in the second dimension, followed by immunoblotting with BUD14 antibodies to detect modified forms.

• Mass Spectrometry Verification: After immunoprecipitation with BUD14 antibodies, perform mass spectrometry analysis to:

  • Identify specific modified residues

  • Quantify stoichiometry of modifications

  • Discover novel, unexpected modifications

Research has shown that BUD14 promotes Bfa1 dephosphorylation in anaphase, as cells lacking BUD14 accumulated hyperphosphorylated Bfa1 forms during this cell cycle stage . While this indicates BUD14's role in regulating the phosphorylation state of its targets, the phosphorylation state of BUD14 itself and how it might be regulated remains an area requiring further investigation. The protocols outlined above would be valuable for addressing this knowledge gap.

How can researchers use BUD14 antibodies to investigate contradictory findings regarding Cdc14 localization and function?

Resolving contradictory findings regarding Cdc14 localization and its relationship to BUD14 function requires sophisticated immunofluorescence approaches:

• High-Resolution Co-Localization Studies: Implement advanced microscopy techniques to precisely map the spatial relationship between BUD14 and Cdc14:

  • Super-resolution microscopy (SIM, STORM, or PALM)

  • Structured illumination with deconvolution

  • Multi-angle TIRF microscopy for surface-proximal interactions

• Temporal Resolution of Interaction Dynamics: Study the temporal relationship between BUD14 and Cdc14 across mitotic progression:

  • Synchronize cells and collect samples at 2-3 minute intervals through anaphase

  • Use antibodies against both proteins with distinct fluorophores

  • Quantify co-localization coefficients at each timepoint

• SPB-Specific Quantification Protocol:

  • Focus specifically on Cdc14-GFP fluorescence intensity at daughter SPBs (dSPBs) in late anaphase (spindle length >6 μm)

  • Compare wildtype cells with bud14Δ mutants and Bud14-F379A mutants

  • Apply statistical methods such as two-way ANOVA for comparing results across multiple conditions

• Functional Relationship Experiments:

  • Use BUD14 antibodies in cells with temperature-sensitive cdc14 mutations

  • Apply Cdc14 antibodies in various BUD14 mutant backgrounds

  • Implement co-immunoprecipitation studies to determine if BUD14-Glc7 and Cdc14 exist in the same or separate complexes

Research has shown that Cdc14 localization to the SPBs is affected by BUD14 function, with particular impact on the daughter spindle pole body . Quantitative fluorescence analysis revealed significant differences in Cdc14-GFP intensity at dSPBs in late anaphase when comparing wildtype cells to bud14Δ mutants . These findings suggest a functional relationship between BUD14 and Cdc14 localization patterns that may help resolve contradictory observations about their respective roles in mitotic exit regulation.

What are the best practices for combining genetic approaches with BUD14 antibody techniques?

Integrating genetic approaches with antibody-based techniques provides powerful insights into BUD14 function:

• Mutant Panel Construction and Analysis:

  • Develop a comprehensive panel of BUD14 mutants including:

    • Deletion mutants (bud14Δ)

    • Point mutations disrupting specific interactions (e.g., Bud14-F379A for formin binding)

    • Truncation mutants targeting different functional domains

    • Chimeric proteins swapping domains with related proteins

  • For each mutant, implement systematic antibody-based analyses:

    • Localization patterns via immunofluorescence

    • Protein interaction profiles via co-immunoprecipitation

    • Post-translational modification states via phospho-specific methods

• Genetic Interaction Mapping with Antibody Phenotyping:

  • Construct double mutants combining bud14Δ with mutations in:

    • SPOC components (e.g., kin4Δ, bfa1Δ, bub2Δ)

    • Mitotic exit network (e.g., lte1Δ, cdc15-1, dbf2-2, mob1-67)

    • Actin regulatory factors (e.g., tpm1Δ, aip1Δ)

    • SPB components (e.g., spc110 mutants)

  • For each genetic interaction, use antibodies to quantify:

    • SPB protein levels and modifications

    • Actin organization patterns

    • Mitotic checkpoint component localization and modification

• Phenotype Suppression Analysis:

  • Implement suppression assays to identify functional relationships:

    • Test if bud14Δ suppresses temperature sensitivity of MEN mutants (cdc15-1, dbf2-2, mob1-67)

    • Evaluate if bud14Δ rescues cold sensitivity of lte1Δ cells

    • Determine if bud14Δ suppresses the lethality of mitotic exit deficient lte1Δ spo12Δ cells

  • For each suppression relationship, use BUD14 antibodies to assess molecular mechanisms

Research has demonstrated successful application of these integrated approaches. For example, bud14Δ was found to rescue cold sensitivity of lte1Δ cells, lethality of mitotic exit-deficient lte1Δ spo12Δ cells, and growth defects of MEN temperature-sensitive mutants . Additionally, the functional separation between BUD14's role in formin regulation versus mitotic exit inhibition was established by showing that the Bud14-F379A mutant (which cannot bind to formin Bnr1) remained functional for mitotic exit inhibition .